Experimental CAR t therapy targets Hard-to-Treat cancers in first human trial
NCT ID NCT05568680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize and attack cancer cells that have a protein called mesothelin, and then giving them back as a one-time infusion. The main goals are to see if it is safe and feasible, and to find the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SynKIR-110 (a type of CAR T cell therapy made from the patient's own immune cells, engineered to target mesothelin on cancer cells)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 42 participants, so it is primarily testing safety, not effectiveness. The therapy may cause serious side effects like cytokine release syndrome or nerve problems, and it may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Kansas Cancer Center
ACTIVE_NOT_RECRUITINGWestwood, Kansas, 66205, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact